Karnataka Mail

Facioscapulohumeral Muscular Dystrophy Market

The Facioscapulohumeral Muscular Dystrophy therapeutics market is anticipated to grow in the coming years owing to the increasing prevalent population of FSHD patients in the 7MM, extensive research and development activities of pharmaceutical companies, along with the expected launch of emerging therapies in the market.

Several major pharma and biotech companies, such as Fulcrum Therapeutics, Dyne Therapeutics, GSK, Roche, Facio Therapies, Myocea, Avidity Biosciences, and others, are persistently working towards developing new treatment therapies for FSHD. The launch of pipeline therapies is expected to transform the treatment scenario in the coming years immensely.

DelveInsight’s “Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Facioscapulohumeral Muscular Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Facioscapulohumeral Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Facioscapulohumeral Muscular Dystrophy Overview

Facioscapulohumeral muscular dystrophy is a genetic disorder characterized by progressive muscle weakness and wasting. Here’s an overview of its causes, symptoms, diagnosis, and treatment:

Facioscapulohumeral Muscular Dystrophy Causes:

FSHD is caused by mutations in the DUX4 gene. Normally, this gene is turned off in adult cells, but in people with FSHD, it remains active, leading to the production of toxic proteins that damage muscle cells. FSHD can be inherited in an autosomal dominant pattern, meaning that only one copy of the mutated gene is needed to cause the disorder. However, not everyone with the mutation will necessarily develop symptoms, and the severity of symptoms can vary widely even among affected family members.

Facioscapulohumeral Muscular DystrophySymptoms:

Symptoms of FSHD typically begin in late childhood to early adulthood, although onset can occur at any age. Common symptoms include:

• Progressive weakness and wasting of muscles, particularly in the face (facio-), shoulders (scapulo-), and upper arms (humeral).
• Difficulty with tasks requiring arm elevation, such as reaching overhead or lifting objects.
• Facial weakness, including difficulty smiling, closing the eyes completely, or whistling.
• Shoulder blade (scapular) winging, where the shoulder blades protrude from the back.
• Variable progression and severity of symptoms, even among affected family members.
• Diagnosis:
• Diagnosing FSHD typically involves a combination of clinical evaluation, genetic testing, and muscle biopsies. The diagnosis is often suspected based on the pattern of muscle weakness and family history. Genetic testing can confirm the presence of mutations in the DUX4 gene, while muscle biopsies may show specific changes consistent with the disorder.

Facioscapulohumeral Muscular Dystrophy Treatment:

Currently, there is no cure for FSHD, and treatment focuses on managing symptoms and improving quality of life. Treatment options may include:

• Physical therapy: Exercises to maintain muscle strength, flexibility, and range of motion can help manage symptoms and delay progression.
• Assistive devices: Devices such as braces, orthotics, or wheelchairs may be used to support weakened muscles and improve mobility.
• Speech therapy: For individuals with facial weakness affecting speech and swallowing, speech therapy can help improve communication and swallowing function.
• Pain management: Medications or other interventions may be prescribed to manage pain associated with muscle weakness and joint problems.
• Research and clinical trials: There is ongoing research into potential treatments for FSHD, including gene therapy and other targeted therapies. Participation in clinical trials may be an option for some individuals.

Facioscapulohumeral Muscular Dystrophy Market Key Facts

• In 2021, the total Facioscapulohumeral Muscular Dystrophy market size was USD 25.55 million, which is expected to rise during the study period.
• The total market size of FSHD in the United States was USD 19.83 million in 2021.
• In Japan, the total market size of FSHD was USD 2.39 million in 2021.
• In the year 2021, the total Facioscapulohumeral Muscular Dystrophy prevalent cases were 78,790 in the 7MM, which is expected to grow during the study period, i.e., 2019–2032.
• In the 7MM, the highest number of total prevalent cases of FSHD were observed in the United States, with 33,500+ cases in 2021.
• The total prevalent cases of FSHD in EU4 and the UK comprised 32,800+ cases in 2021.
• According to DelveInsight’s analysis, in EU4 and the UK, the highest number of total prevalent cases of FSHD was observed in Germany in 2021.

Facioscapulohumeral Muscular Dystrophy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Facioscapulohumeral Muscular Dystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Facioscapulohumeral Muscular Dystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Facioscapulohumeral Muscular Dystrophy Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Facioscapulohumeral Muscular Dystrophy (FSHD) Epidemiology, Segmented by –

• Total Prevalent Cases of Facioscapulohumeral Muscular Dystrophy
• Total Diagnosed Cases of Facioscapulohumeral Muscular Dystrophy
• Total Type-specific Cases of Facioscapulohumeral Muscular Dystrophy
• Total Gender-specific Cases of Facioscapulohumeral Muscular Dystrophy
• Total Age-specific Cases of Facioscapulohumeral Muscular Dystrophy
• Total Severity-specific Cases of Facioscapulohumeral Muscular Dystrophy
• Total Treated Cases of Facioscapulohumeral Muscular Dystrophy

Facioscapulohumeral Muscular Dystrophy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Facioscapulohumeral Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the Facioscapulohumeral Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Facioscapulohumeral Muscular Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Facioscapulohumeral Muscular Dystrophy Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market

Facioscapulohumeral Muscular Dystrophy Therapeutics Analysis

Currently, there are no treatments that modify the progression of Facioscapulohumeral Muscular Dystrophy (FSHD). Instead, supportive care serves as the cornerstone of managing the condition. This care primarily revolves around physical therapy and rehabilitation exercises. It’s crucial to address pain and fatigue in FSHD patients, as both can significantly impact their psychological well-being. Chronic pain can be effectively managed with a combination of analgesic and antidepressant therapy, aiming to enhance the overall quality of life for individuals with FSHD. Globally, several prominent companies are actively engaged in advancing therapeutic options within the Facioscapulohumeral Muscular Dystrophy market landscape, with the aim of improving treatment outcomes.

Prominent Players in the Facioscapulohumeral Muscular Dystrophy Therapeutics Market Include:

• Fulcrum Therapeutics
• GSK
• Roche
• And Many More

Facioscapulohumeral Muscular Dystrophy Therapies Covered in the Report Include:

• Losmapimod: Fulcrum Therapeutics
• RG6237: Roche
• And Many Others

Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market

Table of Contents

1. Key Insights

2. Executive Summary 

3. Facioscapulohumeral Muscular Dystrophy Competitive Intelligence Analysis

4. Facioscapulohumeral Muscular Dystrophy Market Overview at a Glance

5. Facioscapulohumeral Muscular Dystrophy Disease Background and Overview

6. Facioscapulohumeral Muscular Dystrophy Patient Journey

7. Facioscapulohumeral Muscular Dystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Facioscapulohumeral Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Facioscapulohumeral Muscular Dystrophy Unmet Needs

10. Key Endpoints of Facioscapulohumeral Muscular Dystrophy Treatment

11. Facioscapulohumeral Muscular Dystrophy Marketed Products

12. Facioscapulohumeral Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances

13. Facioscapulohumeral Muscular Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Facioscapulohumeral Muscular Dystrophy Market Outlook (In US, EU5, and Japan)

16. Facioscapulohumeral Muscular Dystrophy Access and Reimbursement Overview

17. KOL Views on the Facioscapulohumeral Muscular Dystrophy Market

18. Facioscapulohumeral Muscular Dystrophy Market Drivers

19. Facioscapulohumeral Muscular Dystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/